TrialGynecologic oncology2011

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Lydia Usha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.